Advertisement

Topics

Keytruda-Pemetrexed-Platinum Chemotherapy Combination Significantly Improved Overall Survival in Late-Stage NSCLC Study

13:32 EDT 16 Apr 2018 | Speciality Pharma Journal

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from KEYNOTE-189, a pivotal Phase 3 trial evaluating KEYTRUDA®, Merck’s anti-PD-1 therapy, in combination with pemetrexed (ALIMTA®) and cisplatin or carboplatin for the first-line treatment of metastatic nonsquamous non-small cell lung cancer (NSCLC). Findings showed that the KEYTRUDA-pemetrexed-platinum …

Original Article: Keytruda-Pemetrexed-Platinum Chemotherapy Combination Significantly Improved Overall Survival in Late-Stage NSCLC Study

NEXT ARTICLE

More From BioPortfolio on "Keytruda-Pemetrexed-Platinum Chemotherapy Combination Significantly Improved Overall Survival in Late-Stage NSCLC Study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...